메뉴 건너뛰기




Volumn 133, Issue 41, 2011, Pages 16477-16485

Prospective CCR5 small molecule antagonist compound design using a combined mutagenesis/modeling approach

Author keywords

[No Author keywords available]

Indexed keywords

ALLOSTERIC INHIBITOR; ANTI-VIRAL DRUGS; BINDING MODES; EXTRACELLULAR LOOP 2; IN-VITRO; IN-VITRO EVALUATION; INTERACTION SITE; MEDICINAL CHEMISTRY; PHARMACOPHORES; SMALL MOLECULES; STRUCTURAL REQUIREMENTS;

EID: 80054763142     PISSN: 00027863     EISSN: 15205126     Source Type: Journal    
DOI: 10.1021/ja2043722     Document Type: Article
Times cited : (18)

References (52)
  • 6
    • 77953097279 scopus 로고    scopus 로고
    • Perry, C. M. Drugs 2010, 70, 1189-1213
    • (2010) Drugs , vol.70 , pp. 1189-1213
    • Perry, C.M.1
  • 20
    • 84857108862 scopus 로고    scopus 로고
    • Merck, accessed on February 16, 2011
    • Merck, 2010. http://www.merck.com/newsroom/news-release-archive/research- and-development/2010-0217.html; accessed on February 16, 2011.
    • (2010)
  • 21
    • 33745581733 scopus 로고    scopus 로고
    • Crabb, C. AIDS 2006, 20, 641
    • (2006) AIDS , vol.20 , pp. 641
    • Crabb, C.1
  • 39
  • 40
    • 84857118765 scopus 로고    scopus 로고
    • log D is a measure of lipophilicity: ACD/PhysChemBatch; ACD/Labs Release: 12.00 Product Version: 12.01
    • log D is a measure of lipophilicity: ACD/PhysChemBatch; ACD/Labs Release: 12.00 Product Version: 12.01; www.acdlabs.com.


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.